Diuretics vs. placebo for postpartum blood pressure control in preeclampsia (DIUPRE): a randomized clinical trial

Telma Cursino, Leila Katz, Isabela Coutinho, Melania Amorim, Telma Cursino, Leila Katz, Isabela Coutinho, Melania Amorim

Abstract

Background: Hypertension affects about 10% of pregnancies and is responsible for both maternal and neonatal devastating complications such as eclampsia, HELLP syndrome, prematurity and maternal and neonatal death. The resolution of the disease occurs in the first twelve weeks postpartum. The behavior of blood pressure and occurrence of very high blood pressure episodes among women with severe preeclampsia is related to remodeling of the dynamics of body fluids with consequent increase in intravascular volume. The persistence of hypertension in critical levels results in increased puerperal morbidity.

Objectives: To evaluate the effectiveness of furosemide in accelerating blood pressure recovery among women with severe preeclampsia.

Methods/design: A triple-masked placebo controlled clinical trial, will be conducted including 120 postpartum women with severe preeclampsia, after eclampsia prophylaxis with magnesium sulfate and with adequate diuresis. Women with chronic hypertension and users of diuretics will be deleted. Informed consent will be obtained from all participants. Patients will be randomized to receive furosemide (40 mg orally every twenty four hours) or placebo. The variables are systolic and diastolic blood pressure, frequency of hypertensive crises, need for maintenance of antihypertensive therapy, number of antihypertensive agents used to control blood pressure, urine output, length of hospital stay, adverse effects and maternal complications. This study was approved by the Research Ethics Committee in humans of our institution. All participants will be duly informed about the aims of the project and will be included only if they agree to participate voluntarily, signing the informed consent.

Trial registration: This study was registered on Clinical Trials.gov under the number NCT02163655. ( https://ichgcp.net/clinical-trials-registry/NCT02163655).

Figures

Fig. 1
Fig. 1
Study design and population (CONSORT, 2010) [27]

References

    1. Roberts CL, Ford JB, Algert CS, Antonsen S, Chalmers J, Cnattingius S, et al. Population-based trends in pregnancy hypertension and pre-eclampsia: an international comparative study. BMJ Open. 2011;1(1):e000101.
    1. Hutcheon JA, Lisonkova S, Joseph KS. Epidemiology of preeclampsia and the other hypertensive disorders of pregnancy. Best Pract Res Clin Obstet Gynaecol. 2011;25(4):391–403. doi: 10.1016/j.bpobgyn.2011.01.006.
    1. Ronsmans C, on behalf of the Lancet Maternal Survival Series steering group. Graham WJ. Maternal mortality; who, when, where and why. Lancet. 2006;368(9542):1189–200. doi: 10.1016/S0140-6736(06)69380-X.
    1. Zanette E, Parpinelli MA, Surita FG, Costa ML, Haddad SM, Sousa MH, et al. Brazilian Network for Surveillance of Severe Maternal Morbidity Group.Maternal near miss and death among women with severe hypertensive disorders: a Brazilian multicenter surveillance study. Reprod Health. 2014;11(1):4. doi: 10.1186/1742-4755-11-4.
    1. Ray JG, Vermeulen MJ, Schull MJ, Redelmeier DA. Cardiovascular health after maternal placental syndromes (CHAMPS): populationbased retrospective cohort study. Lancet. 2005;366(9499):1797–803. doi: 10.1016/S0140-6736(05)67726-4.
    1. Ray JG, Schull MJ, Kingdom JC, Vermeulen MJ. Heart failure and dysrhythmias after maternal placental syndromes: HAD MPS Study. Heart. 2012;98(15):1136–41. doi: 10.1136/heartjnl-2011-301548.
    1. American College of Obstetricians and Gynecologists; Task Force on Hypertension in Pregnancy Hypertension in pregnancy. Report of the American College of Obstetricians and Gynecologists’ Task Force on Hypertension in Pregnancy. Obstet Gynecol. 2013;122(5):1122–31. doi: 10.1097/01.AOG.0000437382.03963.88.
    1. Tranquilli AL, Dekker G, Magee L, Roberts J, Sibai BM, Steyn W, et al. The classification, diagnosis and management of the hypertensive disorders of pregnancy: a revised statement from the ISSHP. Pregnancy Hypertension. 2014;4(2):97–104.
    1. von Dadelszen P, Magee LA. Pre-eclampsia: an update. Curr Hypertens Rep. 2014;16(8):454. doi: 10.1007/s11906-014-0454-8.
    1. Duley Lelia, Gülmezoglu A Metin, Henderson-Smart David J, Chou Doris. Magnesium sulphate and other anticonvulsants for women with pre-eclampsia. Cochrane Database of Systematic Reviews. In: The Cochrane Library, Issue 11, Art. No. CD000025. doi:10.1002/14651858.CD000025.pub3
    1. Duley Lelia, Henderson-Smart David J, Walker Godfrey JA, Chou Doris. Magnesium sulphate versus diazepam for eclampsia. Cochrane Database of Systematic Reviews. In: The Cochrane Library, Issue 11, Art. No. CD000127. doi:10.1002/14651858.CD000127.pub2
    1. Duley Lelia, Henderson-Smart David J, Chou Doris. Magnesium sulphate versus phenytoin for eclampsia. Cochrane Database of Systematic Reviews. In: The Cochrane Library,Issue 11, Art. No. CD000128. doi:10.1002/14651858.CD000128.pub2
    1. Duley Lelia, Gülmezoglu A Metin, Chou Doris. Magnesium sulfate versus lytic cocktail for eclampsia. Cochrane Database of Systematic Reviews. In: The Cochrane Library, Issue 11, Art. No. CD002960. doi:10.1002/14651858.CD002960.pub1
    1. Duley Lelia, Matar Hosam E, Almerie Muhammad Qutayba, Hall David R. Alternative magnesium sulphate regimens for women with pre-eclampsia and eclampsia. Cochrane Database of Systematic Reviews. In: The Cochrane Library, Issue 11, Art. No. CD007388. doi:10.1002/14651858.CD007388.pub8
    1. Norwitz ER. Eclampsia. In: UpToDate 2015. Topic 1662 Version 27.0. ©2015 UpToDate®.
    1. Churchill David, Duley Lelia, Thornton Jim G, Jones Leanne. Interventionist versus expectant care for severe pre-eclampsia between 24 and 34 weeks' gestation. Cochrane Database of Systematic Reviews. In: The Cochrane Library, Issue 11, Art. No. CD003106. doi:10.1002/14651858.CD003106.pub3
    1. Koopmans CM, Bijlenga D, Groen H, Vijgen SM, Aarnoudse JG, Bekedam DJ, et al. Induction of labour versus expectant monitoring for gestational hypertension or mild pre-eclampsia after 36 weeks' gestation (HYPITAT): a multicentre, open-label randomized controlled trial. Lancet. 2009;374(9694):979–88. doi: 10.1016/S0140-6736(09)60736-4.
    1. Sanctos M. Evolução dos níveis pressóricos no puerpério em mulheres com pré-eclâmpsia grave atendidas em um hospital terciário: estudo de coorte [dissertação] Recife: Instituto de Medicina Integral Professor Fernando Figueira-IMIP; 2004.
    1. Chames MC, Livingston JC, Ivester TS, Barton JR, Sibai BM. Late postpartum eclampsia: a preventable disease? Am J Obstet Gynecol. 2002;186:1174–1177. doi: 10.1067/mob.2002.123824.
    1. Duley L. The global impact of pre-eclampsia and eclampsia. Semin Perinatol. 2009;33:130–137. doi: 10.1053/j.semperi.2009.02.010.
    1. Castro LC, Hobel CJ, Gornbein J. Plasma levels of atrial natriuretic peptide in normal and hypertensive pregnancies: a meta-analysis. Am J Obstet Gynecol. 1994;171:1642–1651. doi: 10.1016/0002-9378(94)90416-2.
    1. Davison JM, Dunlop W. Changes in renal hemodynamics and tubular function induced by human normal pregnancy. Semin Nephrol. 1984;4:198–207.
    1. Ascarelli MH, Johnson V, McCreary H, Cushman J, May WL, Martin JN Jr. Postpartum preeclampsia management with furosemide: a randomized clinical trial. Obstetrics and gynecology. 2005;105(1):29–33.
    1. Pearson JF. Fluid balance in severe preeclampsia. Br J Hosp Med. 1992;48:47–51.
    1. Magee Laura, von Dadelszen Peter. Prevention and treatment of postpartum hypertension. Cochrane Database of Systematic Reviews. In: The Cochrane Library, Issue 11, Art. No. CD004351. doi:10.1002/14651858.CD004351.pub1
    1. Matthews G, Gornall R, Saunders N. A randomized placebo trial of loop diuretics in moderate/severe preeclampsia, following delivery. J Obstet Gynaecol. 1997;17:30–2. doi: 10.1080/01443619750114040.
    1. Schulz KF, Altman DG, Moher D, CONSORT Group CONSORT 2010 statement: updated guidelines for reporting parallel group randomized trials. BMJ. 2010;340:c332. doi: 10.1136/bmj.c332.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe